Search Results - "Dunphy, Mark"

Non-invasive metabolic imaging of brain tumours in the era of precision medicine by Kim, Michelle M., Parolia, Abhijit, Dunphy, Mark P., Venneti, Sriram

“…Key Points Brain tumours, such as gliomas, in adults and children are morphologically similar, but harbour different genomic alterations, both across and…”
Get full text

The epichaperome is an integrated chaperome network that facilitates tumour survival by Rodina, Anna, Wang, Tai, Yan, Pengrong, Gomes, Erica DaGama, Dunphy, Mark P. S., Pillarsetty, Nagavarakishore, Koren, John, Gerecitano, John F., Taldone, Tony, Zong, Hongliang, Caldas-Lopes, Eloisi, Alpaugh, Mary, Corben, Adriana, Riolo, Matthew, Beattie, Brad, Pressl, Christina, Peter, Radu I., Xu, Chao, Trondl, Robert, Patel, Hardik J., Shimizu, Fumiko, Bolaender, Alexander, Yang, Chenghua, Panchal, Palak, Farooq, Mohammad F., Kishinevsky, Sarah, Modi, Shanu, Lin, Oscar, Chu, Feixia, Patil, Sujata, Erdjument-Bromage, Hediye, Zanzonico, Pat, Hudis, Clifford, Studer, Lorenz, Roboz, Gail J., Cesarman, Ethel, Cerchietti, Leandro, Levine, Ross, Melnick, Ari, Larson, Steven M., Lewis, Jason S., Guzman, Monica L., Chiosis, Gabriela

“…Chaperomes are dynamic assemblies of proteins that regulate cellular homeostasis but specific cellular stresses remodel chaperome components into a stable…”
Get full text

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC by Hellmann, Matthew D, Nabet, Barzin Y, Rizvi, Hira, Chaudhuri, Aadel A, Wells, Daniel K, Dunphy, Mark P S, Chabon, Jacob J, Liu, Chih Long, Hui, Angela B, Arbour, Kathryn C, Luo, Jia, Preeshagul, Isabel R, Moding, Everett J, Almanza, Diego, Bonilla, Rene F, Sauter, Jennifer L, Choi, Hyejin, Tenet, Megan, Abu-Akeel, Mohsen, Plodkowski, Andrew J, Perez Johnston, Rocio, Yoo, Christopher H, Ko, Ryan B, Stehr, Henning, Gojenola, Linda, Wakelee, Heather A, Padda, Sukhmani K, Neal, Joel W, Chaft, Jamie E, Kris, Mark G, Rudin, Charles M, Merghoub, Taha, Li, Bob T, Alizadeh, Ash A, Diehn, Maximilian

“…Treatment with PD-(L)1 blockade can produce remarkably durable responses in patients with non-small cell lung cancer (NSCLC). However, a significant fraction…”
Get full text

Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET by Dunphy, Mark P.S, Lewis, Jason S

“…This review article discusses PET agents, other than (18)F-FDG, with the potential to monitor the response to therapy before, during, or after therapeutic…”
Get full text

The Unique Pharmacometrics of Small Molecule Therapeutic Drug Tracer Imaging for Clinical Oncology by Dunphy, Mark P. S., Pillarsetty, Nagavarakishore

“…Translational development of radiolabeled analogues or isotopologues of small molecule therapeutic drugs as clinical imaging biomarkers for optimizing patient…”
Get full text

Paradigms for Precision Medicine in Epichaperome Cancer Therapy by Pillarsetty, Nagavarakishore, Jhaveri, Komal, Taldone, Tony, Caldas-Lopes, Eloisi, Punzalan, Blesida, Joshi, Suhasini, Bolaender, Alexander, Uddin, Mohammad M., Rodina, Anna, Yan, Pengrong, Ku, Anson, Ku, Thomas, Shah, Smit K., Lyashchenko, Serge, Burnazi, Eva, Wang, Tai, Lecomte, Nicolas, Janjigian, Yelena, Younes, Anas, Batlevi, Connie W., Guzman, Monica L., Roboz, Gail J., Koziorowski, Jacek, Zanzonico, Pat, Alpaugh, Mary L., Corben, Adriana, Modi, Shanu, Norton, Larry, Larson, Steven M., Lewis, Jason S., Chiosis, Gabriela, Gerecitano, John F., Dunphy, Mark P.S.

“…Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic…”
Get full text

FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma by Kadota, Kyuichi, Colovos, Christos, Suzuki, Kei, Rizk, Nabil P., Dunphy, Mark P. S., Zabor, Emily C., Sima, Camelia S., Yoshizawa, Akihiko, Travis, William D., Rusch, Valerie W., Adusumilli, Prasad S.

“…Background We investigated the association between the newly proposed International Association for the Study of Lung Cancer (IASLC)/American Thoracic Society…”
Get full text

Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo by Venneti, Sriram, Dunphy, Mark P, Zhang, Hanwen, Pitter, Kenneth L, Zanzonico, Patrick, Campos, Carl, Carlin, Sean D, La Rocca, Gaspare, Lyashchenko, Serge, Ploessl, Karl, Rohle, Daniel, Omuro, Antonio M, Cross, Justin R, Brennan, Cameron W, Weber, Wolfgang A, Holland, Eric C, Mellinghoff, Ingo K, Kung, Hank F, Lewis, Jason S, Thompson, Craig B

“…Glucose and glutamine are the two principal nutrients that cancer cells use to proliferate and survive. Many cancers show altered glucose metabolism, which…”
Get more information

Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions by Jhaveri, Komal, Ochiana, Stefan O, Dunphy, Mark Ps, Gerecitano, John F, Corben, Adriana D, Peter, Radu I, Janjigian, Yelena Y, Gomes-DaGama, Erica M, Koren, 3rd, John, Modi, Shanu, Chiosis, Gabriela

“…Heat shock protein 90 (HSP90) serves as a critical facilitator for oncogene addiction. There has been augmenting enthusiasm in pursuing HSP90 as an anticancer…”
Get more information

Chaperome heterogeneity and its implications for cancer study and treatment by Wang, Tai, Rodina, Anna, Dunphy, Mark P., Corben, Adriana, Modi, Shanu, Guzman, Monica L., Gewirth, Daniel T., Chiosis, Gabriela

“…The chaperome is the collection of proteins in the cell that carry out molecular chaperoning functions. Changes in the interaction strength between chaperome…”
Get full text

First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET by Krebs, Simone, Veach, Darren R, Carter, Lukas M, Grkovski, Milan, Fornier, Monica, Mauro, Michael J, Voss, Martin H, Danila, Daniel C, Burnazi, Eva, Null, Manda, Staton, Kevin, Pressl, Christina, Beattie, Bradley J, Zanzonico, Pat, Weber, Wolfgang A, Lyashchenko, Serge K, Lewis, Jason S, Larson, Steven M, Dunphy, Mark P S

“…We developed a first-of-kind dasatinib-derivative imaging agent, F-SKI-249380 ( F-SKI), and validated its use for noninvasive in vivo tyrosine kinase-targeted…”
Get full text

Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤2 cm by Nitadori, Jun-ichi, Bograd, Adam J., Morales, Eduardo A., Rizk, Nabil P., Dunphy, Mark P. S., Sima, Camelia S., Rusch, Valerie W., Adusumilli, Prasad S.

“…Purpose Limited resection is an increasingly utilized option for treatment of clinical stage IA lung adenocarcinoma (ADC) ≤2 cm (T1aN0M0), yet there are no…”
Get full text

First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer by Dunphy, Mark P S, Pressl, Christina, Pillarsetty, Nagavarakishore, Grkovski, Milan, Modi, Shanu, Jhaveri, Komal, Norton, Larry, Beattie, Bradley J, Zanzonico, Pat B, Zatorska, Danuta, Taldone, Tony, Ochiana, Stefan O, Uddin, Mohammad M, Burnazi, Eva M, Lyashchenko, Serge K, Hudis, Clifford A, Bromberg, Jacqueline, Schöder, Heiko M, Fox, Josef J, Zhang, Hanwen, Chiosis, Gabriela, Lewis, Jason S, Larson, Steven M

“…I-PU-H71 is an investigational first-in-class radiologic agent specific for imaging tumor epichaperome formations. The intracellular epichaperome forms under…”
Get full text

Pharmacokinetic Assessment of 18F-(2S,4R)-4-Fluoroglutamine in Patients with Cancer by Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D, Harding, James J, Mellinghoff, Ingo K, Humm, John L, Dunphy, Mark PS

“…18F-(2S,4R)-4-fluoroglutamine (18F-FGln) is an investigational PET radiotracer for imaging tumor glutamine flux and metabolism. The aim of this study was to…”
Get full text

Pharmacokinetic Assessment of 18 F-(2 S, 4 R )-4-Fluoroglutamine in Patients with Cancer by Grkovski, Milan, Goel, Reema, Krebs, Simone, Staton, Kevin D, Harding, James J, Mellinghoff, Ingo K, Humm, John L, Dunphy, Mark P S

“…F-(2S,4R)-4-fluoroglutamine ( F-FGln) is an investigational PET radiotracer for imaging tumor glutamine flux and metabolism. The aim of this study was to…”
Get full text

Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer by Schöder, Heiko, França, Paula Demétrio De Souza, Nakajima, Reiko, Burnazi, Eva, Roberts, Sheryl, Brand, Christian, Grkovski, Milan, Mauguen, Audrey, Dunphy, Mark P., Ghossein, Ronald A., Lyashchenko, Serge K., Lewis, Jason S., O'Donoghue, Joseph A., Ganly, Ian, Patel, Snehal G., Lee, Nancy Y., Reiner, Thomas

“…PURPOSEWe performed a first-in-human clinical trial. The aim of this study was to determine safety and feasibility of PET imaging with 18F-PARPi in patients…”
Get full text

Solitary Orbital Metastasis in Carcinoma Esophagus: Findings on Serial 18F-FDG PET/CT Scans by Mahajan, Sonia, Dunphy, Mark P, Haque, Sofia, Pandit-Taskar, Neeta

“…ABSTRACTOrbital metastasis is an uncommon and atypical presentation of recurrent esophageal cancer that has been only seldom reported in literature. F-FDG…”
Get full text

Optimizing 90Y Particle Density Improves Outcomes After Radioembolization by Maxwell, Aaron W. P., Mendoza, Humberto G., Sellitti, Matthew J., Camacho, Juan C., Deipolyi, Amy R., Ziv, Etay, Sofocleous, Constantinos T., Yarmohammadi, Hooman, Maybody, Majid, Humm, John L., Schwartz, Jazmin, Juluru, Krishna, Dunphy, Mark P., Boas, F. Edward

“…Purpose To determine how particle density affects dose distribution and outcomes after lobar radioembolization. Methods Matched pairs of patients, treated with…”
Get full text

Correction to: Optimizing 90Y Particle Density Improves Outcomes After Radioembolization by Maxwell, Aaron W. P., Mendoza, Humberto G., Sellitti, Matthew J., Camacho, Juan C., Deipolyi, Amy R., Ziv, Etay, Sofocleous, Constantinos T., Yarmohammadi, Hooman, Maybody, Majid, Humm, John L., Schwartz, Jazmin, Juluru, Krishna, Dunphy, Mark P., Boas, F. Edward

Get full text

High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology by Kadota, Kyuichi, Kachala, Stefan S, Nitadori, Jun-Ichi, Suzuki, Kei, Dunphy, Mark P S, Sima, Camelia S, Travis, William D, Rusch, Valerie W, Adusumilli, Prasad S

“…We have recently proposed to reclassify the pleomorphic subtype of epithelioid malignant pleural mesothelioma (MPM) as nonepithelioid (biphasic/sarcomatoid)…”
Get more information